Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upM. Dreyling, Marco Ladetto, Elı́as Campo et al.|Annals of Oncology|2017Cited by 736
Prognostic significance of bcl-2 protein expression in aggressive non- Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA)Olivier Hermine, Philippe Gaulard|Blood|1996Cited by 417
Prognostic significance of bcl-2 protein expression in aggressive non- Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA)Olivier Hermine, Philippe Gaulard|Blood|1996Cited by 411
Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KITPatrice Dubreuil, Olivier Hermine|PLoS ONE|2009Cited by 409
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Martin Dreyling, Jürgen Finke et al.|The Lancet|2016Cited by 401